DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...

Alembic has received permission from the Food and Drug Administration for brexpiprazole tablets, which is the generic of Otsuka’s Rexulti. Brexpiprazole is an atypical antipsychotic used as an ...

Otsuka and Lundbeck are seeking another indication for brexpiprazole, an atypical antipsychotic, combining it with sertraline, a selective serotonin reuptake inhibitor, to treat adults with ...

Brexpiprazole is under clinical development by Otsuka Pharmaceutical and currently in Pre-Registration for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Pre-Registration drugs for ...

Brexpiprazole is an atypical antipsychotic used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, and also used in treatment of schizophrenia ...

Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Brexpiprazole Tablets.

Vadodara: Alembic Pharmaceuticals Limited has announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for ...

Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brexpiprazole Tablets ...

Otsuka and Lundbeck are seeking another indication for brexpiprazole, an atypical antipsychotic, combining it with sertraline, a selective serotonin reuptake inhibitor, to treat adults with post ...